View:

Download DOC

Download PDF

Download XLS

Consistent with Bilirubin Transporter Mechanism END OF TREATMENT RESULTS FROM LIMT HDV STUDY: A PHASE 2 RANDOMIZED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGYLATED INTERFERON LAMBDA MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA VIRUS INFECTION O. Etzion1*, S. Hamid2*, Y. Lurie3, E. J. Gane4, David Yardeni1, N. Bader2, A Nevo-Shor1, S. M. Channa5, M. Mawani2, O. Parkash2, K Yang6, D Longo6, R Gish7, D. Apelian8, J. Glenn7 1. Gastroenterology and Liver Disease Institute, Soroka University Medical Center, Beer-Sheva, Israel ; 2. Aga Khan University and Hospital, Karachi, Pakistan; 3. Shaare Zedek Medical Center, Jerusalem, Israel; 4. Auckland City Hospital, Auckland, New Zealand 5. Department of Gastroenterology, Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan; 6. DILISym®, USA; 7. Stanford University School of Medicine; 8. Eiger BioPharmaceuticals, Inc. *These authors share lead authorship 1. ABSTRACT CONCLUSIONS Background and Aims: Hepatitis Delta Virus (HDV) infection leads to the most aggressive form of human viral hepatitis. There is no approved therapy. Worldwide prevalence of HDV infection is 15-20 million. Pegylated interferon-alfa (Alfa), a Type I IFN, has previously demonstrated a mean HDV RNA decline up to ~2.5 log10 at 48 weeks of treatment (Wedemeyer, NJEM 2011). PEG IFN-lambda-1a (Lambda), a Type III IFN, has previously demonstrated a good tolerability profile in >3000 HBV and HCV patients, with fewer episodes of cytopenias, flu-like, and psychiatric symptoms compared to Alfa. The goal of this study was to evaluate safety and efficacy of Lambda monotherapy in patients with HDV infection. Methods: Randomized, open-label study of Lambda 120 or 180 μg, weekly SC injections for 48 weeks in patients with chronic HDV, conducted in Pakistan, Israel, and New Zealand. Dose reductions were permitted. Major inclusion criteria: positive HDV RNA by qPCR (Robogene® 2.0, BLQ 14 IU/mL), ALT<10×ULN, and compensated liver disease. Tenofovir or entecavir were started at baseline (BL). Results: This study enrolled 33 patients, randomized to Lambda 180 μg (N=14), and 120 μg (N=19), respectively. BL mean values: HDV RNA 4.1 log10 IU/mL (SD±1.4); ALT 106 IU/L (35-364) and bilirubin 0.5 mg/dL (0.2-1.2). At Week 48, patients in the 180 μg Lambda treated group experienced a -2.3 log10 mean decline in HDV-RNA, with 7 of 11 (63.6%) experiencing ≥2 log10 decline, 5 of 11 (45.5%) patients were HDV-RNA negative at end of treatment. At Week 48, patients in the 120 μg Lambda treated group experienced a -1.1 log10 mean decline in HDV RNA, with 5 of 13 (38.5%) experiencing ≥2 log10 decline, 3 of 13 (23.1%) patients were HDV-RNA negative at end of treatment. The most common adverse events included mild to moderate flu-like symptoms and elevated transaminase levels. Patients previously treated with Alfa noted significantly less side effects on Lambda. Overall, Lambda was well tolerated. Increased incidences of clinical jaundice and bilirubin elevations were observed in the Pakistani cohort, leading to a lower rate of study completion (9 of 15, 60%) compared to patients from Israel and New Zealand (15 of 18; 83%). None of the patients with elevations in bilirubin showed symptoms of decompensation and all responded favorably to dose reduction or dose discontinuation. DILIsym® modeling of ALT and bilirubin dynamics indicates a transporter-based mechanism for the observed bilirubin elevations. Conclusions: After 48 weeks of treatment, Lambda 180 μg had comparable antiviral activity with better tolerability, compared to historical data for Alfa. Elevated bilirubin levels in a subset of patients are likely due to alteration in bilirubin transport, and not due to meaningful hepatocellular injury. Pharmacogenomic studies are planned to better understand the increased incidence of bilirubin changes in Pakistani patients. Lambda is a promising agent for mono or combination Rx (i.e. lonafarnib) development in the treatment of HDV. 2. ABOUT HDV 3. ABOUT PEGYLATED INTERFERON LAMBDA 4. LIMT HDV STUDY 5. BASELINE CHARACTERISTICS Leads to the most severe form of human viral hepatitis Always associated with HBV infection HDV causes more rapid disease progression Compared to HBV mono-infection No FDA approved Rx 15-20 M HDV-infected patients worldwide >100K patients in US; >200K patients in EU 4-6% of HBV infected patients are coinfected with HDV A novel first in class Type III interferon Binds to a unique Type III receptor Highly expressed on hepatocytes Limited expression on hematopoietic cells and CNS cells Uses similar downstream signaling pathway as Type I interferons Greater than 3,000 patients in 17 clinical trials (HCV / HBV) have been dosed with IFN lambda Comparable antiviral activity with less severe IFN alfa side effects* Limited Extra-Hepatic Lambda Receptor Distribution Potential for LESS IFN-associated abnormalities Neutropenia Thrombocytopenia Flu-like Symptoms Musculoskeletal Symptoms Evaluate safety, tolerability and efficacy Evaluate the proportion of patients with undetectable HDV RNA 12 weeks after the end of treatment 24 weeks after the end of treatment Median Characteristic Values Values N 33 Age, years (range) 36 (20, 63) Male, n (%) 22 (66.7%) Race, n (%) White Black Pacific Islander Other 13 (39.4%) 1 (3.0%) 4 (12.1%) 15 (45.5%) BMI, kg/m2 (range) 24.7 (14.0, 37.1) HDV-RNA, log10 IU/mL (SD) 4.1 ± 1.4 ALT, U/mL (range) 106 (35, 364) Platelets, x109/L (range) 170 (95, 281) Albumin, g/dL (range) 4.4 (3.7, 5.2) INR 1.2 (1.0, 1.5) Bilirubin, mg/dL (range) 0.5 (0.2, 1.2) HDV-RNA Reduction with Lambda thru Week 48 Dose* Randomized Completers Dose Reductions Of Patients Completing Week 48 Responders Rebounders Non-Responders 120 mcg 19 13 / 19 (68.4%) 5 / 19 (26.3%) 6 / 13 (46.2%) 4 / 13 (30.8%) 0 180 mcg 14 11 / 14 (78.6%) 7 / 14 (50.0%) 9 / 11 (81.8%) 2 / 11 (18.2%) 0 a Flu-like symptoms: pyrexia, cough, sore throat, runny/stuffed nose, myalgia/arthralgia, headache, asthenia, vomiting, diarrhea b Psychiatric symptoms: depression, irritability, insomnia c 11 of 18 events experienced by 4 patients in Pakistan site AE of Special Interest % Patients Reporting Lambda 120 / 180 mcg Grade 1 Grade 2 Grade 3 Grade 4 Flu-like symptomsa 97% (32/33) 225 53 3 - Psychiatric symptomsb 3% (1/33) 1 - - - Cytopenia 15% (5/33) 2 3 - 2 Thrombocytopenia 0% (0/33) - - - - Elevated bilirubinc 30% (10/33) 12 3 3 - Elevated ALT 27% (9/33) 12 4 - - Adverse Events Higher Incidence of Hyperbilirubinemia* in Pakistan Cohort Hyperbilirubinemia in 4/15 (27%) of Pakistani versus 2/18 (11%) of non-Pakistani cohort Jaundice observed in 3/15 (20%) of Pakistani patients versus 0/18 (0%) of non-Pakistani patients Incidence/Severity in non-Pakistani cohort consistent with prior Lambda and Alfa data in HBV* Patients with bilirubin elevations did not experience signs or symptoms of decompensation Bilirubin levels were responsive to dose reduction/interruption Patients exhibited normal hepatic function (Prothrombin time) throughout periods of bilirubin elevation DILIsym® Modeling of ALT/Bilirubin Dynamics ALT and bilirubin dynamics consistent with bilirubin transporter based mechanism Dynamics are not consistent with hyperbilirubinemia secondary to hepatocyte loss Supported by absence of clinical decompensation Supported by normal hepatic function (normal PT) throughout cases of bilirubin elevation Pharmacogenomic assessment of bilirubin transporters in Pakistan cohort is planned to better understand cohort specific increase in incidence and severity of hyperbilirubinemia Of the 24 patients who reached Week 48: 120 μg group (N=14) Mean HDV RNA decline = 1.1 log10 ≥2 log10 decline in 5 of 13 (38.5%) 180 μg group (N=10) Mean HDV RNA decline = 2.3 log10 ≥2 log10 decline in 7 of 11 (63.6%) Lambda was well tolerated overall Increased incidences of clinical jaundice and bilirubin elevations were observed in the Pakistani cohort Led to lower than expected rate of study completion (9 of 15, 60%) for Pakistan site Israel and New Zealand sites had completion rates (15 of 18, 83%) comparable to prior Alfa studies None of the patients with elevations in bilirubin showed symptoms of decompensation All responded favorably to dose reduction or dose discontinuation Lambda demonstrates comparable anti-HDV activity to historical PEG IFN Alfa data at Week 48 Lambda was well-tolerated overall Most commonly reported AEs: moderate headache, pyrexia, fatigue, and myalgia ALT flares are due to vigorous antiviral immunological response to treatment, not due to direct hepatotoxicity DILIsym® modeling indicates a transporter-based mechanism for the observed bilirubin elevations Elevated bilirubin levels likely due to alteration in bilirubin transport; not due to hepatocellular injury Lambda is a promising agent for mono or combination Rx (i.e. lonafarnib) development in the treatment of HDV 6. RESULTS Responders*: 180 mcg Group 7. OBSERVATIONS 8. CONCLUSIONS Milder and fewer flu-like and psychiatric symptoms with Lambda No thrombocytopenia events Elevated bilirubin and ALT levels normalized upon dose reduction or treatment discontinuation Lambda 180 mcg Demonstrates Better Antiviral Activity Consistent with Bilirubin Transport Mechanism Objectives Study Sites: 33 Patients Randomized Auckland, New Zealand (N=4) Karachi, Pakistan (N=15) Beersheba, Israel (N=11) Jerusalem, Israel (N=3) Lambda Interferon MonoTherapy Study in HDV Predominantly Grade 1 Lambda 120 mcg vs 180 mcg No Signs or Symptoms of Decompensation * Hyperbilirubinemia = > 2 mg/mL Completers = completion of 48 week of treatment Responders = ≥2 log decline or below limit of quantification (BLQ) Rebounders = increase >2 log HDV RNA from nadir Non-responders = <1 log decline during treatment * Randomization Dose * Chan et al, Hepatology 2016 Exhibit 99.1 Exhibit 99.1

Growing Hepatitis Delta Virus (HDV) Infection Prevalence in the US: Underdiagnosis in Foreign-born Individuals R Franco1, J Glenn2, R Gish2,3, D Apelian1 Eiger BioPharmaceuticals1, Stanford University School of Medicine2, Hepatitis B Foundation3 BACKGROUND Hepatitis Delta Virus (HDV) infection leads to the most aggressive form of human viral hepatitis. It is estimated that 4-6% of the HBV-infected population is co-infected with HDV. In the US the rate of co-infection is believed to be 3-5%, however targeted testing may yield significantly higher rates of HDV positivity. For example, testing HBsAg (+) patients may yield positivity rates between 8-12% (Gish 2012 and Martins 2017). Worldwide prevalence of HDV infection is between 15-20 million. Global migration in the last decade has shifted HDV-infected population into the western world. US prevalence of HDV infection is estimated to be between 110,000 (Martins 2017) and 135,000 (DelveInsight 2018). This may be an underestimate due to underdiagnosis in foreign-born individuals. This epidemiological study sought to: (1) estimate the number of foreign-born individuals with HDV in the US and (2) identify areas of the US with high HDV prevalence and opportunities to improve screening and diagnosis based upon the composition of foreign-born individuals. METHODS Our analysis combined Symphony Health Solutions’ (SHS) Integrated Universe’s PatientSourceTM database, US Census Data of foreign-born populations from 109 countries and published HBV and HDV epidemiology studies (Kowdley 2012, Alfaiate 2015). SHS is a comprehensive longitudinal patient database with over 4 billion prescription, medical, and hospital claims linked to anonymous patient identifiers, practitioners and payers. The patient database includes claims’ information for over 274 million patients, accounting for over 73% of all prescriptions, over 58% of all electronically processed medical claims and 25% of all hospital claims. The entire dataset is linked to each de-identified patient, with 75% of patients with a linked prescription and diagnosis claim. This analysis focuses predominately on those countries with a known HDV prevalence rate among people infected with HBV and whose foreign-born population is tracked by the US Census Bureau to the zip code level. Limitations to this study include the capture rates from SHS database and the finite number of countries captured in the US census data. Both limitations are likely to underestimate the number of foreign-born people in the US with HDV. Top 20 Countries with Largest HBV-Infected Population in the US > 1.1 MILLION FOREIGN-BORN, HBV-INFECTED PATIENTS IN THE US RESULTS ICD-10Description B17.0 Hepatitis delta without mention of active hepatitis B disease or hepatic coma B16.0 Viral hepatitis B with hepatic coma, acute or unspecified, with hepatitis delta B16.1 Viral hepatitis B without mention of hepatic coma, acute or unspecified, with hepatitis delta B18.0 Chronic viral hepatitis B without mention of hepatic coma with hepatitis delta > 50,000 HDV-INFECTED PATIENTS DIAGNOSED BETWEEN 2008-2016 COUNTRIES WITH FOREIGN-BORN IN US WITH HIGHEST PREVALENCE OF HDV The US Census Bureau tracks the foreign-born population at the zip code level for most countries with a moderate to high (> 10%) HDV prevalence rate among those infected with HBV. * There are a select number of countries with a high HDV prevalence rate are not tracked by the US Census Bureau (i.e. Mongolia, Central African Republic). This data is not included in this analysis. HDV AMONG FOREIGN-BORN PEOPLE WITH HBV U.S. CITIES WITH HIGHEST PREVALENCE OF HDV TOP US CITIES WHERE HDV IS MOST PREVALENT AND THE ESTIMATED NUMBER OF FOREIGN-BORN PEOPLE WITH HDV US Cities Where HDV is Likely Underdiagnosed Based Solely on the Composition of Foreign-born Individuals City Total # Diagnosed with HDV (2008-2016) Estimated Number of Foreign-born Individuals with HDV Estimated Number of Foreign-born Individuals with HDV, NOT Diagnosed Minneapolis, MN 165 665.7 -500.7 Lawrenceville, GA 297 781.4 -484.4 Grand Prairie, TX 268 683.7 -415.7 Westminster, CA 148 498.9 -350.9 Ashburn, VA 118 461.3 -343.3 Malden, MA 445 775.9 -330.9 Redmond, WA 222 540.8 -318.8 Katy, TX 162 480.6 -318.6 Pacoima, CA 82 392.9 -310.9 UNDERDIAGNOSIS OF HDV IN THE US In the US, the number of newly diagnosed HDV patients has grown consistently (2008-2016) It is estimated there are at least 55,000 foreign-born individuals with HDV in the US. HDV is no longer limited to the East and West coasts of the US. HDV testing among chronic HBV patients and foreign-born individuals is recommended. Current US HDV prevalence of 110,000 individuals may be an underestimate. CONCLUSIONS 1 2 3 4 5 6 7 Country Foreign-born in US (#) HBV Prevalence (%) HBV Population (#) HDV Prevalence Among HBV (%) HDV Population (#) Romania 177,035 7.2% 12,729 47.6% 6,059 Pakistan 282,507 4.2% 11,781 40.0% 4,712 Albania 79,562 12.4% 9,858 40.0% 3,943 Vietname 1,149,355 12.5% 143,440 2.5% 3,586 Colombia 617,738 1.2% 7,413 40.0% 2,965 Bangladesh 139,773 4.8% 6,751 40.0% 2,700 Brazil 356,531 1.8% 6,346 40.0% 2,539 Turkey 110,212 5.3% 5,863 40.0% 2,345 Somalia 69,333 12.4% 8,597 25.0% 2,149 Kenya 80,657 5.7% 4,597 40.0% 1,839 Afghanistan 59,699 10.5% 6,245 25.0% 1,561 Egypt 136,159 4.6% 6,277 20.0% 1,255 Venezuela 159,655 1.9% 3,081 40.0% 1,233 Ethiopia 151,879 9.6% 14,465 7.5% 1,092 Moldova 43,970 9.6% 4,226 25.0% 1,056 City # Diagnosed HDV 2008-2016 Estimated # of Foreign-born with HDV % Foreign-born with HDV Brooklyn, NY 4,195 1,346 32% Chicago, IL 3,672 620 17% Bronx, NY 2,767 582 21% Corona, NY 2,736 1,251 46% Huntington Station, NY 2,261 369 16% New York, NY 1,755 435 25% Jamaica, NY 1,261 791 63% Scarsdale, NY 943 187 20% Berwyn, IL 933 129 14% Philadelphia, PA 833 472 57% Passaic, NJ 790 698 88% Houston, TX 786 840 107% Miami, FL 700 946 135% San Francisco, CA 674 223 33% Hileah, FL 580 684 118% Parkville, MD 571 200 35% Gainesville, FL 543 52 10% Yonkers, NY 539 114 21% Oviedo, FL 539 150 28% Hempstead, NY 523 195 37% Total 27,601 10,284 Country HDV Prevalence in HBV-Infected Patients (%) Romania 48% Kenya 40% Bangladesh 40% Pakistan 40% Turkey 40% Albania 40% Brazil 40% Colombia 40% Venezuela 33% Somalia 10% Afghanistan 10% Saudi Arabia 10% Latvia 10% 32 countries account for 80% of the foreign-born population in the US. Nearly 50% of those foreign-born people with HBV come from China, Vietnam and the Philippines. HDV prevalence rates are known for 31 countries whose foreign-born population is tracked by the US Census Bureau. Based upon ICD-10 codes, there were 53,186 unique patients diagnosed with HDV in the US from 2008-2016. This includes all patients diagnosed with HDV regardless of their birth country. The diagnosis of HDV in the US is steadily increasing as HDV testing becomes readily accessible and potential treatments advance through development. Country Foreign-Born Living in US 2009 (#) HBV Prevalence (%) HBV Population (#) China 1,987,625 12.3% 243,484 Vietnam 1,149,355 12.5% 143,440 Philippines 1,733,864 7.4% 127,612 Dominican Republic 791,593 10.7% 84,542 Western Africa 534,058 13.2% 70,335 Mexico 11,478,234 0.5% 56,243 India 1,665,055 3.2% 53,781 Korea 1,012,911 5.3% 53,279 Guatemala 790,508 3.7% 29,407 Nigeria 207,031 13.3% 27,556 Laos 195,988 13.6% 26,674 Haiti 535,966 4.8% 25,780 Jamaica 644,958 3.9% 25,411 Cambodia 144,379 10.3% 14,828 Ghana 109,091 13.4% 14,662 Ethiopia 151,879 9.6% 14,565 Romania 177,035 7.2% 12,729 Thailand 205,280 6% 12,255 Pakistan 282,507 4.2% 11,781 Russia 405,731 2.89% 11,726 Comparing the number of unique patients diagnosed by city and the estimated number of foreign-born HDV patients in that city, it is possible to identify cities where HDV may be underdiagnosed. Top 20 US cities where HDV is most prevalent have been identified. It is estimated that 10,284 foreign-born people in the US reside in these top 20 cities where HDV is most prevalent. HDV prevalence rates in foreign-born in these cities range from 14-100%. There are at least 55,000 foreign-born people infected with HDV in the US. Foreign-born people infected with HDV represent approximately 40% of all HDV patients in the US. Approximately 50% of all foreign-born HDV patients come from either Romania, Pakistan, Albania, Vietnam or Colombia. Exhibit 99.2